Navigation Links
Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
Date:2/19/2009

LONDON, February 19 /PRNewswire-FirstCall/ --

- Eisai Set to Become an Emerging Leader in the Treatment of Epilepsy

Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), and Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, CEO Dr Luis Portela) today announced the signing of a licence and co-promotion agreement in which Eisai receives a sole license to market, promote and distribute the novel once daily anti-epileptic Zebinix(R) (eslicarbazepine acetate), within Europe(1).

Under the terms of the agreement, Bial will receive EUR95million consisting of an upfront payment plus milestone payments for further epilepsy approvals within Europe. Bial will maintain ongoing development and production rights and the option to co-promote with Eisai throughout Europe and will supply finished product to Eisai.

Zebinix(R), subject to approval by the European Medicines Agency (EMEA), will initially be indicated for the adjunctive treatment of partial-onset seizures, with or without secondary generalisation, in patients 18 years and older with epilepsy. Zebinix(R) was submitted to the EMEA by Bial in March 2008 and approval is anticipated in Q2 2009.

The safety and efficacy of Zebinix(R) has been shown in three phase III double-blind, randomised placebo-controlled trials in 1,049 patients with partial onset seizures. Additionally, these subjects were followed up long term in an open label extension. In these studies, Zebinix(R) demonstrated significant sustained improvements in seizure frequency, reduced depressive symptoms, and significantly improved scores in health related quality of life.

"It is as important to consider the implications on the quality of a patient's day-to-day life, as well as effective seizure control, when making the therapeutic evaluation
'/>"/>

SOURCE Eisai Europe Ltd and Bial
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... LAUREL, N.J., July 1 MedQuist Inc.,(Pink ... community hospital,located in Westfield, Mass., has selected ... to provide hospital-wide,dictation, transcription and speech recognition ... recognition capability will be,used throughout the hospital ...
... and Bruce Bradley (General,Motors) - to Serve as ... ABIM Foundation,will dedicate its efforts over the next ... and accountability in health care toward the,ultimate goal ... Foundation announced that officers of its Board of,Trustees ...
... WALTHAM, Mass., July 1 Repligen Corporation,(Nasdaq: RGEN ... has been,elected to its Board of Directors. Dr. Goldberg ... School. He is a renowned scientist noted in,particular for ... the mechanism by which most proteins are destroyed in,cells. ...
... fed junk food had higher cholesterol, blood fats into ... News) -- Eating an unhealthy diet during pregnancy may ... cholesterol and blood sugar levels, British researchers report. , ... fed one group of females a diet of processed ...
... Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical ... ... Resources, WALTHAM, Mass., July 1 ... on pharmaceutical and,healthcare issues, finds that a weight neutral oral antidiabetic drug ...
... Health Administrator, Meet Aggressive Hospital Opening Schedule; Eases Ongoing IT ... ... Effort, RIOJA, Spain, July 1 TIBCO Software Inc.,(Nasdaq: ... region of Rioja has deployed its real-time integration,infrastructure. The project at ...
Cached Medicine News:Health News:Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition 2Health News:Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition 3Health News:ABIM Foundation Announces New Focus and Governance 2Health News:ABIM Foundation Announces New Focus and Governance 3Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 3Health News:Mom's Unhealthy Diet May Have Long-Term Impact on Baby 2Health News:A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market 2Health News:Rioja Hospital Uses TIBCO Software to Improve Customer Care and Streamline Operations 2
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... Jan. 15, 2014  Novation, the leading health care supply ... IT value-added reseller (VAR) national contracts that expand its ... services at lower costs. These include manufacturer product and ... initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... a Conference Call on Monday, April 14, at 8:30 a.m. E.T. ... ... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced additional results from its,ongoing ... hypercholesterolemia (FH). In FH patients exposed to,mipomersen for as long as ...
... Researchers from the,Barbara Ann Karmanos Cancer ... adding curcumin or resveratrol to conventional chemotherapy,could ... chemo-resistant colon cancer,cells. The poster presentation was ... (AACR) Annual Meeting in San Diego, CA., ...
Cached Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
... Supplemental Confirmatory (Western Blot): The assay uses ... on their surface. The cells are fixed ... slide. Fixed, uninfected T-cells are provided as ... sample with HIV- I antibodies comes in ...
Bi-phasic peristaltic infusion pump for tumescent work....
... The Klein Pump provides ... requiring tumescent infiltration. Operates on ... off switch with safety Interlock ... Single Spike Tubing, Double Spike ...
... state of the art Aspirator offers ... It can accommodate up to 5 ... eliminating time consuming canister changes. The ... powerful performance with minimal noise. It ...
Medicine Products: